Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the ...

<?xml encoding="utf-8" ?> A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index up 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%. The iShares Biotechnolog ...

U.S. stocks closed higher on Friday, led by a tech-sector rebound, with the Dow surging more than 400 points and all three major indexes ...

Novavax jumped 20% and Moderna rose 7% after a Russian lab worker died from suspected plague exposure. Vaccine and biodefense ...

Gilead’s $7.8 billion buyout of Arcellx closed in April. The more durable return may be the operators that deal released into ...

Vaccine stocks including Novavax and Moderna rallied after a lab technician died following suspected plague exposure at a ...

Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanofi ...

Novavax surged 20% and Moderna gained 7% after a Russian lab worker died from suspected plague exposure. Biodefense and ...

It’s October and time for flu shots.Medical experts urge getting a flu vaccination soon, before influenza starts spreading ...